

SyrSpend[®] SF for hospitalised patients



Tailored, safe and efficient

SyrSpend[®] SF comprises a range of innovative oral suspension vehicles that provide safe, stable and broadly compatible options for compounding tailor-made treatments.

Based on food starch, SyrSpend[®] SF has superior suspending properties and excellent chemical compatibility that allow for compounding with a broad range of active pharmaceutical ingredients (APIs).

SyrSpend[®] SF is easy to swallow with a light texture and no medicinal after taste, which improves patient comfort, compliance and ease of use. Free of harmful ingredients, thus minimising toxic and other side effects, SyrSpend[®] SF

can offer solutions for treatments in hospitals.

The unique *active suspending technology* allows for the preparation of a homogenous suspension that increases the dosage safety for the duration of treatment.

Easy to use and delivering a quickly compounded solution for even the most challenging cases. SyrSpend[®] SF can also be administered through a (naso)gastric tube.

SyrSpend[®] SF's wide-ranging compatibility is supported by multiple scientific stability studies published in peer reviewed international journals and Fagron's convenient compatibility table.

SyrSpend[®] SF is free of the following ingredients that can have toxicological effects, induce allergic reactions or cause irritation of the gastro-intestinal tract:

- Benzyl alcohol
- Carrageenan
- Colourants
- Dextrose
- Ethanol
- Gluten
- Glycerol
- Lactose
- Parabens
- Propylene glycol
- Sorbitol
- Sucrose
- Xylitol
- Common food allergens

The benefits of SyrSpend[®] SF

- Active suspending technology
- Ingredient safety
- Proven compatibility
- Patient comfort
- High compounding efficiency
- Exceptional quality

SyrSpend[®] SF employs *active suspending technology*:

- Low viscosity when shaken eases rehomogenisation
- High viscosity at rest keeps the API safely suspended

Ensuring high dosing accuracy and consistency throughout treatment.

Visit fagron.gr for more information on the unique properties of SyrSpend[®] SF, to access the compatibility table, the Compounding Matters formulations database and the Fagron Academy.

fagron.gr



SyrSpend® SF vehicles are convenient, safe and efficient for the preparation of oral liquid dosage forms. All vehicles are taste-masking with a pleasant sweet taste and available in neutral flavour for easy acceptance by the patient. Compatible with an extensive range of APIs, you can choose the most suitable product for compounding with both acid and alkaline options.

Easy to use

SYRSPEND® SF PH4 (LIQUID)

- Gently preserved with <0.1% sodium benzoate
- Buffered to pH 4.2 for maximum compatibility
- Also available in cherry flavour
- 473 ml suspension



Direct compounding in dispensing container

SYRSPEND® SF PH4 (DRY, FOR RECONSTITUTION)

- Buffered to pH 4.2 for maximum compatibility
- Preservative free
- Pre-weighed powder to make 100 ml or 200 ml suspensions



SYRSPEND® SF ALKA (DRY, FOR RECONSTITUTION)

- Buffered to pH >7 for acid-labile APIs
- Preservative free
- Pre-weighed powder to make 100 ml or 200 ml suspensions



Compounding kits for maximum efficiency

SYRSPEND® SF COMPOUNDING KITS

- Kits contain SyrSpend® SF (dry, for reconstitution) in a validated dispensing container, pre-weighed API powder, oral syringe, tip extender, press-in bottle adapter and compounding instructions



SyrSpend® SF example formulations

Hypertension Amlodipine (as besilate) 1 mg/ml in SyrSpend® SF PH4 (dry)	Cardiac dysrhythmia Atenolol 1 mg/ml in SyrSpend® SF PH4 (dry)	Hypersalivation Glycopyrronium bromide 0.5 mg/ml in SyrSpend® SF PH4 (liquid)
Fungal infection Ketoconazole 20 mg/ml in SyrSpend® SF PH4 (dry)	GERD Omeprazole 2 mg/ml in SyrSpend® SF Alka (dry)	Pulmonary arterial hypertension Sildenafil citrate 2.5 mg/ml in SyrSpend® SF PH4 (liquid)
Nausea and vomiting Domperidone 5 mg/ml in SyrSpend® SF PH4 (dry)	Epilepsy Gabapentin 50 mg/ml in SyrSpend® SF PH4 (liquid)	Inflammatory bowel disease Sulfasalazine 100 mg/ml in SyrSpend® SF PH4 (liquid)

Disclaimer: While a great deal of effort has been spent to ensure the accuracy of the formulations contained herein, no claims are made as to the uses, safety, efficacy or bioavailability of these recommendations. The content of this brochure cannot be construed as (medical) advice, recommendation or opinion. Medical professionals, doctors and compounding pharmacists using this information are advised to do so solely if appropriate in their own professional opinion and judgement. Fagron does not accept and cannot be held responsible or liable in any case for the formulations or information contained herein.